MedTrace Logo

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

NCT04127019 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2079

Last updated 2020-02-26

No results posted yet for this study

Summary

We aimed to evaluate the noninferiority of a short-term anthracycline-free chemotherapy (TC, six cycles of docetaxel and cyclophosphamide) or a short-term anthracycline-based chemotherapy (CEF-T, three cycles of cyclophosphamide/epirubicin/fluorouracil followed by three cycles of docetaxel) to a standard anthracycline/taxane-containing chemotherapy (EC-P, epirubicin and cyclophosphamide for four cycles followed by paclitaxel for twelve weeks) in operable breast cancer.

Conditions

  • Primary Breast Cancer

Interventions

DRUG

Paclitaxel

Paclitaxel chemotherapy (injection)

DRUG

Docetaxel

Docetaxel chemotherapy (injection)

DRUG

Cyclophosphamide

Cyclophosphamide chemotherapy (injection)

DRUG

Epirubicin

Epirubicin chemotherapy (injection)

DRUG

5-fluorouracil

5-fluorouracil chemotherapy (injection)

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Zhi-Ming Shao · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-01
Primary Completion
2017-06-01
Completion
2017-06-15

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04127019 on ClinicalTrials.gov